XML 28 R9.htm IDEA: XBRL DOCUMENT
v3.22.2

Fair Value Measurements and Fair Value of Financial Instruments | 6 Months Ended
--- | ---
Jun. 30, 2022
Fair Value Disclosures [Abstract] |
Fair Value Measurements and Fair Value of Financial Instruments | Fair Value Measurements and Fair Value of Financial Instruments The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. The following is a summary of the Company’s cash equivalents and short-term investments:
| June 30, 2022
| Amortized Cost Basis |  | Unrealized Gains |  | Unrealized Losses |  | Estimated Fair Value
| (In thousands)
Level 1: |  |  |  |  |  |  |
Money market funds | $ | 10,108 |  |  | $ | — |  |  | $ | — |  |  | $ | 10,108 |
Level 2: |  |  |  |  |  |  |
U.S. government and agency securities | 55,150 |  |  | — |  |  | (1,008) |  |  | 54,142 |
Commercial paper | 150,364 |  |  | — |  |  | (323) |  |  | 150,041 |
Corporate bonds | 7,060 |  |  | — |  |  | (48) |  |  | 7,012 |
Total cash equivalents and short-term investments | 222,682 |  |  | — |  |  | (1,379) |  |  | 221,303 |
Less: cash equivalents | (77,342) |  |  | — |  |  | 10 |  |  | (77,332) |
Total short-term investments | $ | 145,340 |  |  | $ | — |  |  | $ | (1,369) |  |  | $ | 143,971 |
| December 31, 2021
| Amortized Cost Basis |  | Unrealized Gains |  | Unrealized Losses |  | Estimated Fair Value
| (In thousands)
Level 1: |  |  |  |  |  |  |
Money market funds | $ | 10,311 |  |  | $ | — |  |  | $ | — |  |  | $ | 10,311 |
Level 2: |  |  |  |  |  |  |
U.S. government and agency securities | 62,268 |  |  | — |  |  | (218) |  |  | 62,050 |
Commercial paper | 177,215 |  |  | 1 |  |  | (61) |  |  | 177,155 |
Corporate bonds | 47,323 |  |  | — |  |  | (39) |  |  | 47,284 |
Total cash equivalents and short-term investments | 297,117 |  |  | 1 |  |  | (318) |  |  | 296,800 |
Less: cash equivalents | (25,808) |  |  | — |  |  | 1 |  |  | (25,807) |
Total short-term investments | $ | 271,309 |  |  | $ | 1 |  |  | $ | (317) |  |  | $ | 270,993 |
As of June 30, 2022, all of the marketable securities have a remaining maturity of less than one year. Management regularly reviews all of the Company’s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company’s marketable securities as of June 30, 2022 were temporary in nature and none were in a continuous loss position for 12 months or more. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Management concluded that none of the Company’s marketable securities were other-than-temporarily impaired as of June 30, 2022. During the three months ended June 30, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. Refer to Note 4, Balance Sheet Components for additional information.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration